6 Aug 2018 Jahr - FDA issued the draft guidance for industry,
“Opioid Use Disorder: Endpoints for
Demonstrating Effectiveness of Drugs for
Medication-Assisted Treatment,” which is
intended to assist sponsors in developing drugs
for medication-assisted treatment of opioid use
disorder (OUD) and addresses the clinical
endpoints acceptable to demonstrate
effectiveness of such drugs.
Zugefügt zum Band der Zeit:
Opioids and the FDA
Datum:
